Literature DB >> 12588987

Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription.

Liang-Nian Song1, Roger Herrell, Stephen Byers, Salimuddin Shah, Elizabeth M Wilson, Edward P Gelmann.   

Abstract

Beta-catenin is a multifunctional molecule that is activated by signaling through WNT receptors. beta-Catenin can also enhance the transcriptional activity of some steroid hormone receptors such as the androgen receptor and retinoic acid receptor alpha. Androgens can affect nuclear translocation of beta-catenin and influence its subcellular distribution. Using mammalian two-hybrid binding assays, analysis of reporter gene transcription, and coimmunoprecipitation, we now show that beta-catenin binds to the androgen receptor ligand-binding domain (LBD) and modulates the transcriptional effects of TIF2 and the androgen receptor N-terminal domain (NTD). In functional assays, beta-catenin bound to androgen receptor only in the presence of ligand agonists, not antagonists. Beta-catenin binding to the androgen receptor LBD was independent of and cooperative with the androgen receptor NTD and the p160 coactivator TIF2, both of which bind to the activation function 2 (AF-2) region of the androgen receptor. Different mutations of androgen receptor helix 3 amino acids disrupted binding of androgen receptor NTD and beta-catenin. beta-Catenin, androgen receptor NTD, and TIF2 binding to the androgen receptor LBD were affected similarly by a subset of helix 12 mutations, but disruption of two sites on helix 12 affected only binding of beta-catenin and not of TIF2 or the androgen receptor NTD. Mutational disruption of each of five LXXLL peptide motifs in the beta-catenin armadillo repeats did not disrupt either binding to androgen receptor or transcriptional coactivation. ICAT, an inhibitor of T-cell factor 4 (TCF-4), and E-cadherin binding to beta-catenin also blocked binding of the androgen receptor LBD. We also demonstrated cross talk between the WNT and androgen receptor signaling pathways because excess androgen receptor could interfere with WNT signaling and excess TCF-4 inhibited the interaction of beta-catenin and androgen receptor. Taken together, the data show that beta-catenin can bind to the androgen receptor LBD and modulate the effects of the androgen receptor NTD and TIF2 on transcription.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588987      PMCID: PMC151689          DOI: 10.1128/MCB.23.5.1674-1687.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

1.  Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain.

Authors:  B He; J A Kemppainen; J J Voegel; H Gronemeyer; E M Wilson
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

Review 2.  Nuclear receptor coactivators.

Authors:  C K Glass; D W Rose; M G Rosenfeld
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

Review 3.  Nuclear receptor coactivators and corepressors.

Authors:  K B Horwitz; T A Jackson; D L Bain; J K Richer; G S Takimoto; L Tung
Journal:  Mol Endocrinol       Date:  1996-10

Review 4.  The Yin-Yang of TCF/beta-catenin signaling.

Authors:  N Barker; P J Morin; H Clevers
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

Review 5.  beta-catenin signaling and cancer.

Authors:  P J Morin
Journal:  Bioessays       Date:  1999-12       Impact factor: 4.345

Review 6.  Androgen receptor mutations in prostate cancer.

Authors:  E R Barrack
Journal:  Mt Sinai J Med       Date:  1996 Oct-Nov

7.  TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors.

Authors:  J J Voegel; M J Heine; C Zechel; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

Review 8.  Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.

Authors:  P Koivisto; T Visakorpi; O P Kallioniemi
Journal:  Scand J Clin Lab Invest Suppl       Date:  1996

9.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Authors:  C W Gregory; B He; R T Johnson; O H Ford; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

Review 10.  Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy.

Authors:  Z Culig; A Hobisch; A Hittmair; M V Cronauer; C Radmayr; G Bartsch; H Klocker
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

View more
  64 in total

1.  Dehydroepiandrosterone administration or G{alpha}q overexpression induces {beta}-catenin/T-Cell factor signaling and growth via increasing association of estrogen receptor-{beta}/Dishevelled2 in androgen-independent prostate cancer cells.

Authors:  Xunxian Liu; Julia T Arnold; Marc R Blackman
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

Review 2.  Chemistry and structural biology of androgen receptor.

Authors:  Wenqing Gao; Casey E Bohl; James T Dalton
Journal:  Chem Rev       Date:  2005-09       Impact factor: 60.622

3.  Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1.

Authors:  Catherine K Yang; Jeong Hoon Kim; Hongwei Li; Michael R Stallcup
Journal:  J Biol Chem       Date:  2005-12-12       Impact factor: 5.157

4.  Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing.

Authors:  Olivera Stojadinovic; Harold Brem; Constantinos Vouthounis; Brian Lee; John Fallon; Michael Stallcup; Ankit Merchant; Robert D Galiano; Marjana Tomic-Canic
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

5.  Role of the N-terminal activation domain of the coiled-coil coactivator in mediating transcriptional activation by beta-catenin.

Authors:  Catherine K Yang; Jeong Hoon Kim; Michael R Stallcup
Journal:  Mol Endocrinol       Date:  2006-08-24

6.  Conditional deletion of beta-catenin mediated by Amhr2cre in mice causes female infertility.

Authors:  Jennifer A Hernandez Gifford; Mary E Hunzicker-Dunn; John H Nilson
Journal:  Biol Reprod       Date:  2009-01-28       Impact factor: 4.285

Review 7.  Ecdysteroid hormone action.

Authors:  Klaus-Dieter Spindler; C Hönl; Ch Tremmel; S Braun; H Ruff; M Spindler-Barth
Journal:  Cell Mol Life Sci       Date:  2009-12       Impact factor: 9.261

Review 8.  Revisiting the role of Wnt/β-catenin signaling in prostate cancer.

Authors:  Jeffrey A Schneider; Susan K Logan
Journal:  Mol Cell Endocrinol       Date:  2017-02-09       Impact factor: 4.102

9.  Activator protein 2alpha associates with adenomatous polyposis coli/beta-catenin and Inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells.

Authors:  Qingjie Li; Roderick H Dashwood
Journal:  J Biol Chem       Date:  2004-08-24       Impact factor: 5.157

10.  Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines.

Authors:  Marcy E Beildeck; Md Islam; Salimuddin Shah; Joellen Welsh; Stephen W Byers
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.